Table 3 Patient characteristics (A) and the surgical and functional outcomes (B) by “L” score in the lateral renal tumors.
L1 (n = 111) | L2 (n = 68) | L3 (n = 84) | P value (L1 vs. L2 vs. L3) | P value (L1 vs. L2, L3) | |||
|---|---|---|---|---|---|---|---|
A. Patient characteristics | |||||||
Age (years) | 61.7 ± 12.7 | 61.7 ± 12.6 | 62.4 ± 13.2 | 0.918 | 0.803 | ||
Sex | Male | 79 (71.2%) | 44 (64.7%) | 61 (72.6%) | 0.534 | 0.715 | |
Medical history | Hypertension | 48 (43.2%) | 31 (45.6%) | 44 (52.4%) | 0.437 | 0.328 | |
Diabetes mellitus | 21 (18.9%) | 8 (11.8%) | 14 (16.7%) | 0.452 | 0.336 | ||
BMI (kg/m2) | 24.0 ± 3.8 | 24.5 ± 4.4 | 25.1 ± 5.2 | 0.197 | 0.114 | ||
RENAL score | Total | 5.2 ± 1.1 | 6.9 ± 1.1 | 7.7 ± 1.3 | <0.001 | < 0.001 | |
R | 1 | 107 (96.4%) | 51 (75.0%) | 71 (84.5%) | < 0.001 | < 0.01 | |
2 | 4 (3.6%) | 17 (25.0%) | 13 (15.5%) | ||||
E | 1 | 62 (55.9%) | 26 (38.2%) | 32 (38.1%) | 0.039 | 0.012 | |
2 | 46 (41.4%) | 39 (57.4%) | 45 (53.6%) | ||||
3 | 3 (2.7%) | 3 (4.4%) | 7 (8.3%) | ||||
N | 1 | 55 (49.5%) | 25 (36.8%) | 36 (42.9%) | 0.207 | 0.076 | |
2 | 34 (30.6%) | 19 (27.9%) | 23 (27.4%) | ||||
3 | 22 (19.8%) | 24 (35.3%) | 25 (29.8%) | ||||
A | a | 50 (45.0%) | 33 (48.5%) | 30 (35.7%) | 0.542 | 0.75 | |
p | 34 (30.6%) | 18 (26.5%) | 28 (33.3%) | ||||
x | 27 (24.3%) | 17 (25.0%) | 26 (31.0%) | ||||
Tumor size | 23.6 ± 9.1 | 29.8 ± 13.3 | 25.7 ± 12.1 | 0.004 | 0.004 | ||
Blood test | Hemoglobin (g/dL) | 14.3 ± 3.4 | 13.6 ± 1.7 | 14.0 ± 1.6 | 0.155 | 0.097 | |
Creatinine (mg/dL) | 0.87 ± 0.30 | 0.92 ± 0.46 | 0.90 ± 0.33 | 0.697 | 0.406 | ||
B. Surgical and functional outcomes | |||||||
Surgical approach | Transperitoneal | 43 (38.7%) | 34 (50.7%) | 31 (36.9%) | 0.179 | 0.484 | |
Console time | 114.6 ± 38.7 | 123.9 ± 39.7 | 111.3 ± 37.3 | 0.126 | 0.64 | ||
Warm ischemia time | 16.3 ± 5.7 | 19.8 ± 6.2 | 17.1 ± 7.2 | 0.001 | 0.013 | ||
Pathological findings | Clear cell | 70 (63.1%) | 52 (76.5%) | 56 (66.7%) | 0.214 | 0.397 | |
pTNM | Benign | 18 (16.4%) | 8 (11.8%) | 5 (6.1%) | 0.189 | 0.124 | |
T1a | 84 (76.4%) | 49 (72.1%) | 64 (78.0%) | ||||
T1b | 5 (4.5%) | 8 (11.8%) | 8 (9.8%) | ||||
T2a | 0 | 0 | 0 | ||||
T3a | 3 (2.7%) | 3 (4.4%) | 5 (6.1%) | ||||
Trifecta achievement | 93 (89.4%) | 47 (78.3%) | 61 (77.2%) | 0.056 | 0.017 | ||
Positive surgical margin | 1 (1.0%) | 0 (0%) | 2 (2.5%) | 0.382 | 0.61 | ||
Perioperative complications | Clavien–Dindo ≧ 2 | 3 (2.7%) | 2 (2.9%) | 3 (3.6%) | 0.939 | 0.543 | |
Pentafecta achievement | 25 (36.8%) | 15 (31.3%) | 15 (30.6%) | 0.734 | 0.434 | ||
Preoperative eGFR | 70.3 ± 20.2 | 67.7 ± 18.8 | 67.2 ± 17.9 | 0.491 | 0.406 | ||
eGFR at 1-year | 60.0 ± 16.8 | 57.8 ± 19.1 | 59.1 ± 16.4 | 0.790 | 0.563 | ||
Preoperative CKD stage | 2.2 ± 0.7 | 2.3 ± 0.7 | 2.3 ± 0.7 | 0.582 | 0.298 | ||
CKD stage at 1-year | 2.4 ± 0.6 | 2.6 ± 0.8 | 2.5 ± 0.7 | 0.553 | 0.312 | ||
